As COVID-19 continues to spread around the globe, researchers and manufacturers are moving potential therapeutics into clinical trials at a dizzying pace.
In the US, funding is led by the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH), while some companies also are funding their own COVID-19 research. Internationally, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) have called for targeted efforts to develop therapies against COVID-19.
While no specifically approved treatments, stakeholders are looking to repurpose approved drugs that have worked against similar coronaviruses in the past or are hypothesized to attack or immobilize SARS-CoV-2 based on the mechanism of action. Plasma and stem cells from patients who have recovered from COVID-19 also are being investigated.
This tracker will be updated weekly with the latest in developments for these treatment candidates…